Patisiran significantly improved neuropathy scores, QoL, walking parameters, nutritional status and activities of daily living compared to placebo.Patisiran reduced mean LV wall thickness, improved GLS and CO, led to increased LVEDV at month 18 and reduced NtproBNP levels at 9 and 18 months compared to placebo.Reduction of 46% in the rate of CV hospitalization and all-cause death. Here, NPPB is linked to neuropathy.